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Objectives In this study, the impact of noninsulin-dependent type 2 diabetes mellitus on carotid wall 18F-fluorodeoxyglucose
(FDG) uptake in patients with documented or suspected cardiovascular disease was evaluated.
Background Inflammation is a pivotal process in the progression of atherosclerosis, which can be noninvasively imaged by
FDG positron emission tomography (FDG-PET).
Methods Carotid artery wall FDG uptake was quantified in 134 patients (age 60.2  9.7 years; diabetic subjects,
n  43). The pre-scan glucose (gluc) level corrected mean of the maximum standardized uptake value (SUV)
values (meanSUVgluc), mean of the maximum target-to-background ratio (meanTBRgluc), and single hottest segment
(SHSgluc) of FDG uptake in the artery wall were calculated. Associations between FDG uptake, the presence of
risk factors for atherosclerosis, and diabetes were then assessed by multiple regression analysis with backward
elimination.
Results The study demonstrated a significant association between diabetes and FDG uptake in the arterial wall (diabe-
tes meanSUVgluc   0.324, meanTBRgluc   0.317, and SHSgluc   0.298; for all, p  0.0001). In addition, in
diabetic patients, both body mass index 30 kg/m2 (meanSUVgluc   0.4, meanTBRgluc   0.357, and SHSgluc
  0.388; for all, p  0.015) and smoking (meanTBRgluc,   0.312; SHSgluc,   0.324; for all, p  0.04) were
significantly associated with FDG uptake.
Conclusions Type 2 diabetes was significantly associated with carotid wall FDG uptake in patients with known or suspected
cardiovascular disease. In diabetic patients, obesity and smoking add to the risk of increased FDG uptake
values. (J Am Coll Cardiol 2012;59:2080–8) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.069Cardiovascular disease (CVD) remains one of the leading
causes of death in the United States, accounting for 1 in every
2.8 deaths (1). It is also known that diabetes mellitus is
associated with a high risk of CVD. Atherosclerotic plaque
inflammation plays a central role in atherosclerotic plaque
progression, vulnerability, and thrombogenicity. The exact
mechanisms underlying the association between diabetes and
atherosclerotic disease are not well known (2). Epidemiological
studies suggest that type 2 diabetes mellitus is not merely an
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associated with increased levels of inflammatory biomarkers
(3). In line with these findings, efforts have been made to use
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noninvasive imaging to quantify vessel wall inflammation and
to provide further evidence of the impact of clinical risk factors
such as diabetes on atherosclerosis.
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June 5, 2012:2080–8 Type 2 Diabetes and Carotid Wall FDG UptakeCarotid 18F-fluordeoxyglucose (FDG) positron emission
tomography (PET) has been shown to reflect the metabolic
rate of glucose, a process known to be enhanced in inflamed
tissue. Uptake of FDG has been shown to be significantly
associated with both the degree of macrophage infiltration
and the levels of inflammatory gene expression in plaques
(4–6). Several clinical CVD risk factors have also been
shown to exhibit a significant association with carotid wall
inflammation (7–9). However, data regarding the impact of
diabetic disease on vessel wall inflammation remain incon-
clusive. Some trials failed to show any association between
diabetes and atherosclerosis as assessed by FDG-PET (8,9),
whereas others have observed a significant association be-
tween diabetic disease and vascular inflammation (7,10).
Tumor PET studies have also shown that FDG accumula-
tion is diminished during hyperglycemia (11–13). This
effect however, has not been evaluated in vascular PET
imaging.
The aim of the present study was to assess the impact of
non–insulin-dependent type 2 diabetes on carotid wall
FDG uptake while seeking to avoid some of the limitations
of previous studies. Therefore, we designed a cross-sectional
study in a larger sample population and performed FDG-
PET imaging with protocols optimized for vessel wall
visualization/analysis (7,9,14).
Methods
Study design. This was a cross-sectional study, investigat-
ing the impact of non–insulin-dependent type 2 diabetes on
the prevalence of carotid wall inflammation assessed by
FDG-PET. This study, approved by the institutional re-
view board, was conducted from February 2006 until Oc-
tober 2010 at the Mount Sinai School of Medicine, New
York. All subjects gave written informed consent.
Inclusion criteria were as follows: male and female sub-
jects with a diagnosis of CVD or subjects with multiple
CVD risk factors were recruited. Cardiovascular disease was
defined as a previous myocardial infarction, stroke, transient
ischemic attack (TIA), history of peripheral artery disease,
or a history of a coronary revascularization procedure.
Patients with insulin-dependent type 2 diabetes and pa-
tients with type 1 diabetic disease were excluded from the
study, as were subjects with fasting glucose levels 11.1
mmol/l or previous carotid surgery.
Questionnaire and biometric and biochemical measurements.
Presence of cardiovascular risk factors, use of medication,
and family history of CVD were assessed by a questionnaire.
Presence of hypertension was defined as a history of systolic
blood pressure 140 mm Hg, or a diastolic blood pressure
90 mm Hg. Diabetes was defined as documented diag-
nosis of type 2 diabetic disease and the use of antidiabetic
treatment (diet or oral, no insulin treatment). Weight and
height were measured to calculate body mass index (BMI).
Smoking was defined as smoking at least 1 cigarette on a
daily basis. Fasting glucose levels were obtained by finger stickblood glucose measurements (Accu-
Chek Advantage, Roche Diagnos-
tics, Indianapolis, Indiana) before
FDG administration.
FDG-PET/computed tomo-
graphy imaging. The FDG-PET/
computed tomography (CT) imag-
ing was performed after an over-
night fast using a Lightspeed discov-
ery ST 16-slice PET/CT scanner
(General Electric Healthcare, Mil-
waukee, Wisconsin). The FDG was
administered intravenously (557.6
84.0 MBq), and patients rested
comfortably for 97 to 193 min
(136.7  21.2 min) before the scan
of the neck was started. Subjects
were placed into a head holder for
imaging of the carotids. A low-dose
CT scan (140 kV, 80 mA, and
4.25-mm slice thickness) was performed for attenuation correc-
tion and coregistration. Images from 1 bed position (15.5 cm)
with coverage extending inferior to the internal auditory meatus
were acquired in 3-dimensional mode using a 128  128 pixel
matrix for 15 min. No CT contrast agent was administered.
he total radiation dose from participating into this study was
pproximately 12 mSv.
mage analysis. Image analysis was performed on a
edicated commercially available workstation (Extended
rilliance Workspace V4.0.0.3206, Philips Medical Sys-
ems, Cleveland, Ohio). An experienced reader (J.B.)
nalyzed all scans. Methodology for analysis and repro-
ucibility of the measurements have been previously
eported (15).
Briefly, arterial FDG uptake was quantified by manually
rawing a region of interest around each artery (common
arotid arteries) on every slice of the coregistered transaxial
ET/CT images. Next, the maximum arterial standardized
ptake value (SUV [highest pixel activity within the region
f interest]) was determined. The SUV is the decay-
orrected tissue concentration of FDG in kBq/ml, adjusted
or the injected FDG dose and the body weight of the
atient. By averaging the maximum SUV values of all
rterial slices of the left and right carotid artery, a meanSUV
alue was derived for the carotid arteries.
The meanSUV values were also corrected for patient’s
fasting pre-scan glucose levels to account for a competitive
impact of glucose (gluc) and FDG using an established
formula (16). The measured glucose content was normal-
ized for an overall population average of 5.0 mmol/l (16) as
follows: meanSUVgluc  meanSUV  patient’s blood glucose
mmol/l)/5.0 mmol/l.
The arterial target-to-background ratio (TBRgluc) was
calculated by normalizing the SUVgluc for blood pool
activity by dividing the SUVgluc value in the artery by the
Abbreviations
and Acronyms
BMI  body mass index
CT  computed
tomography
CVD  cardiovascular
disease
FDG  18F-fluordeoxyglucose
PET  positron emission
tomography
SHS  single hottest
segment
SUV  standardized uptake
value
TBR  target-to-
background ratio
TIA  transient ischemic
attackaverage blood mean SUV estimated from both jugular veins.
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Type 2 Diabetes and Carotid Wall FDG Uptake June 5, 2012:2080–8The TBRgluc is a blood-normalized arterial SUV, consid-
ered to be a reflection of arterial FDG uptake and reflective
of underlying macrophage activity (14). For evaluation of
the FDG blood pool activity, at least 6 3- to 4-mm regions
of interest were placed in consecutive slices of both jugular
veins and averaged.
The arterial TBR values obtained were then averaged to
derive a meanTBRgluc for both carotid arteries. Additionally,
e identified the glucose-corrected single hottest slice
SHSgluc), defined as the highest TBRgluc value of the
carotid arteries.
Statistical analysis. All continuous variables are expressed
as mean  SD, and categorical data as absolute numbers
and percentages throughout this paper. To also assess a
potential relation between continuous BMI values of the
patients and the different FDG uptake parameters instead of
assessing the impact of increased BMI values 30 kg/m2,
earson’s or Spearman’s rho correlation coefficients (r) were
alculated, depending on normal distribution, between the
MI values between the uncorrected- and glucose-corrected
DG uptake parameters in the entire study population as
ell as in the 2 subgroups of patients with and without type
diabetes. In general, normal distribution of data was tested
or all of the different statistical calculations using the
olmogorov-Smirnov test.
SUBGROUP ANALYSIS. The study population was divided
into 2 subgroups of patients, namely, patients with and
patients without diabetes. Furthermore, to test for the effect
of antidiabetic medication on the degree of carotid wall
inflammation, we compared the different FDG uptake
parameters between patient receiving oral antidiabetic
drugs and patients receiving dietary treatment only. For
all comparisons of subgroups of patients, the Student t
test or the Mann–Whitney U test was performed to
compare continuous variables depending on normal dis-
tribution. Categorical variables were compared between
diabetic and nondiabetic patients by using Fisher’s exact
test.
MULTIPLE REGRESSION WITH BACKWARD ELIMINATION
AND LINEAR REGRESSION WITH THE ENTER METHOD.
[Significant variables of the backward elimination entered a
consecutive linear regression model in a block in a single
step. To look at the relationship between each of 1
independent variable on 1 dependent variable, multiple
regression analyses were used in the present study.]
A multiple linear regression analysis with backward
elimination was used to assess the association between the
cardiovascular risk factors and glucose-corrected FDG up-
take parameters (meanSUVgluc, meanTBRgluc, and SHSgluc) in the
ntire study population as well as in both subgroups of
atients with and without diabetes (17,18). The FDG
ptake parameters were treated as the response variables
dependent) and cardiovascular risk factors as the explana-
ory (independent) variables for the regression analysis. The
xplanatory variables included were as follows: age 65ears, male, BMI 30 kg/m2, statin use, type 2 diabetes,
istory of CVD, smoking, alcohol use, hypertension, and
amily history of CVD. To evaluate a potential beneficial
ffect of exercise on carotid wall inflammation, exercise was
of the explanatory variables in the regression analyses.
fter this, the ENTER regression method was used to
etermine independent predictors of the response variables.
or this method, all of the explanatory variables of the
ackward elimination model that showed a significant
ssociation with the FDG uptake value were retained and
ntered into the regression model in a block in a single step.
his entry method was preferred over the forward selection
f variables, because after excluding all of the explanatory
ariables without a significant association with the different
arotid wall FDG uptake values, only a few significant
ariables were left for a relatively low number of cases. A
imilar analysis approach was also followed for the FDG
ptake values obtained without the applied glucose correc-
ion (meanSUV, meanTBR, SHS) (16). Throughout this
paper, all results of the multiregression models were given
with the standardized regression coefficient (), the 95%
onfidence interval, and the p value for the estimate of the
tatistical significance.
TERTILE ANALYSIS. The patients were grouped into tertiles
based on their FDG-PET uptake parameters. Pearson chi-square
tests were performed to compare the prevalence of clinical vari-
ables across the groups of patients classified by tertiles of the
different FDG uptake parameters (meanSUVgluc, meanTBRgluc,
nd SHSgluc).
Analysis of variance with the appropriate adjustment for
ultiple comparisons was performed to compare FDG
ptake values between different levels of fasting glucose in
ondiabetic patients and patients with diabetes (according
o the recommendations by the International Diabetes
ederation IGF/IGT consensus statement [19]). Post-hoc
nalyses were performed using the Tukey test. All statistical
nalyses were performed using the SPSS statistical package,
ersion 16.0 (SPSS, Chicago, Illinois).
esults
opulation characteristics. In all, 134 patients were in-
luded in the study. In 3 of the patients, FDG-PET analysis
ould not be performed because of high FDG uptake in
he thyroid, affecting the visualization and analysis of
DG uptake within the carotid arteries, leaving 131 eligible
atients for image analysis. On average, 7.56  2.49
slices for the left common carotid artery and 7.36  2.5
slices for the right common carotid artery were analyzed
to derive the FDG uptake parameters. Table 1 shows the
characteristics of the whole population, both diabetic and
nondiabetic subjects. There were some differences in
demographics between the diabetic group and nondia-
2083JACC Vol. 59, No. 23, 2012 Bucerius et al.
June 5, 2012:2080–8 Type 2 Diabetes and Carotid Wall FDG UptakeCharacteristics of Study PopulationTable 1 Characteristics of Study Population
Characteristics
Total
(N  134)
Diabetic Subjects
n  43 (32%)
Nondiabetic Subjects
n  91 (68%) p Value
Age, yrs 60.2 10.1 61.3 10.0 59.6 10.2 0.37
Age 65 yrs 46 (34) 16 (37) 30 (33) 0.70
Sex
Male 96 (72) 33 (77) 63 (69)
Female 38 (28) 10 (23) 28 (31) 0.42
BMI, kg/m2 28.9 5.7 29.6 4.8 28.6 6.1 0.34
25 32 (24) 8 (19) 24 (26) 0.39
25 to 30 54 (40) 17 (40) 37 (41) 1.00
30 48 (36) 18 (42) 30 (33) 0.34
Lifestyle
Smoking
Never 58 (43) 19 (44) 40 (44) 1.00
Former 57 (43) 21 (49) 35 (39) 0.35
Cigarettes per day (range) 24.7 14.6 (2–80) 24.4 15.8 (2–60) 24.8 14.3 (3–80) 0.82
Current 19 (14) 3 (7) 16 (18) 0.12
Cigarettes per day (range) 12.6 11.9 (2–40) 3.0 1.0 (2–4) 14.6 12.2 (3–40) 0.004
Alcohol users 50 (37) 12 (28) 38 (42) 0.13
Exercisers 72 (54) 16 (37) 56 (62) 0.010
Times per week 4.46 2.08 5.0 2.4 4.31 2.0 0.34
Time per session, min 46.7 30.0 41.2 22.2 48.1 31.7 0.65
Medical history
Cardiovascular disease
Myocardial infarction 27 (21) 8 (19) 19 (21) 1.00
PCI 60 (45) 25 (58) 35 (39) 0.041
CABG 22 (16) 11 (26) 11 (12) 0.078
Stroke/TIA 11 (8) 2 (5) 9 (10) 0.50
Peripheral artery disease 5 (4) 0 (0) 5 (6) 0.18
Family history of CVD 80 (60) 19 (44) 61 (67) 0.015
Hypertension 90 (67) 32 (74) 58 (64) 0.24
Duration hypertension, months 129.9 119.7 110.5 96.9 142.8 132.4 0.30
Diabetes type 2 43 (32) 43 (100) —
Duration of diabetes, yrs 7.25 7.35 (0.5–34.0) 7.25 7.35 (0.5–34.0) —
Fasting glucose, mmol/l 5.9 1.3 6.8 1.7 5.4 0.8 0.0001
6.1 89 (66) 16 (37) 73 (80) 0.0001
6.1 to 7.0 23 (17) 8 (19) 15 (17) 0.81
7.0 9 (7) 6 (14) 3 (3) 0.030
7.8 13 (10) 13 (30) 0 (0) 0.0001
Medication
Statin 104 (78) 37 (86) 67 (74) 0.13
Duration, months 51.6 64.4 44.3 56.3 54.5 67.7 0.49
Beta-blockers 63 (47) 26 (61) 37 (41) 0.041
CCB 21 (16) 8 (19) 13 (14) 0.61
ACEI 43 (32) 17 (40) 26 (29) 0.24
ATII blockers 20 (15) 6 (14) 14 (15) 1.00
Nitrates 7 (5) 2 (5) 5 (6) 1.00
Diuretics 20 (15) 6 (14) 14 (15) 1.00
Aspirin 91 (68) 30 (70) 61 (67) 0.84
Clopidogrel 61 (46) 23 (54) 38 (42) 0.27
Oral antidiabetics 36 (27) 36 (84) — —
Values are mean SD, n (%), or mean SD (range). Significant differences were found with regard to exercise and family history of cardiovascular
disease (CVD) being higher among nondiabetic patients as well as for percutaneous coronary intervention (PCI) and medication with beta-blockers
being higher for subjects with diabetes. As expected, mean fasting glucose levels as well as increased levels of the classified glucose values were
significantly higher in diabetic patients, whereas glucose values within the normal range were significantly more often found in nondiabetic subjects.
No significant differences between both groups were observed for slightly increased glucose values 6.1 to 7.0 mmol/l.ACEI  angiotensin-converting enzyme inhibitor; ATII  angiotensin II; BMI  body mass index; CABG  coronary artery bypass graft surgery;
CCB  calcium-channel blocker; TIA  transient ischemic attack.
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Type 2 Diabetes and Carotid Wall FDG Uptake June 5, 2012:2080–8betic group (history of percutaneous coronary intervention
and use of beta-blockers being higher among diabetic patients;
exercise, family history of CVD, and cigarettes per day in
current smokers all being higher among nondiabetic patients);
otherwise, the 2 groups were similar. As expected, fasting
glucose was higher in the diabetic population compared with
that of nondiabetic subjects.
FDG-PET imaging results. The imaging analyses of the
groups (Table 2), however, showed that glucose-corrected
FDG-PET parameters (meanSUVgluc, meanTBRgluc, SHSgluc)
were significantly higher in the diabetic group compared
with the nondiabetic group. This difference was not ob-
served in FDG-PET parameters that were not corrected for
pre-scan glucose. Dividing patients into 2 groups according
to their pre-scan glucose values by using the median of these
values, we also found significantly higher values for all glucose-
corrected FDG uptake parameters in diabetic patients in the
group of higher (5.6 to 10.6 mmol/l) pre-scan glucose levels. In
the group of patients with lower pre-scan glucose levels (2.8 to
5.5 mmol/l) all glucose-corrected FDG uptake parameters
were also found to be higher in diabetic patients; however,
these differences failed to be statistically significant (Table 2).
In diabetic patients, no significant differences were observed for
all glucose-corrected FDG parameters between patients
treated with oral antidiabetic drugs and patients on dietary
treatment only (meanSUVgluc p  0.313, meanTBRgluc p 
.314, SHSgluc p  0.122).
FDG-PET imaging and CVD risk factors. Table 3
shows the results of the multiple linear regression analysis
FDG-PET Imaging ResultsTable 2 FDG-PET Imaging Results
FDG-PET/CT
Total
(N  131)
FDG uptake time,* min 136.7 21.2
meanSUV 2.17 0.35
meanSUVgluc 2.53 0.64
meanTBR 1.99 0.32
meanTBRgluc 2.31 0.56
SHS 2.30 0.44
SHSgluc 2.68 0.76
Blood pool activity† 1.11 0.20
Glucose-corrected FDG uptake‡
Group 1 (2.8–5.5 mmol/l) 65
meanSUVgluc 2.17 0.46
meanTBRgluc 2.01 0.41
SHSgluc 2.32 0.51
Group 2 (5.6–10.6 mmol/l) 66
meanSUVgluc 2.89 0.59
meanTBRgluc 2.61 0.54
SHSgluc 3.03 0.80
Values are mean SD, n, or n (%). By averaging the maximum standardized uptake values (SUV) o
By averaging the mean SUV values of all analyzed slices of the left and right jugular vein, the mea
ifferences were found between patients with and without diabetic disease with regard to the FD
iabetic patients, no significant differences between the groups were found for the uncorrected pa
ll glucose values revealed statistically significant differences between patients with type 2 diabete
igher pre-scan glucose levels. *Time difference between FDG injection and starting time of data a
depending on patient’s fasting glucose levels (median 5.5 mmol/l).
CT  computed tomography; PET  positron emission tomography; SHS  single hottest slice;with backward elimination to identify clinical risk factorsassociated with glucose-corrected FDG-PET uptake pa-
rameters (i.e., measures of plaque inflammation). Diabetes
showed the strongest relationship with all FDG-PET
uptake parameters (meanSUVgluc, meanTBRgluc, SHSgluc) fol-
owed by BMI 30 kg/m2. Only risk factors that had a p
alue 0.10 were retained in the model for the ENTER
egression (all significant and therefore retained variables
ntered this model in a block in a single step) and are shown
n Table 3. After the ENTER regression analysis, it was
ound that diabetes, BMI 30 kg/m2, and alcohol use
(except of meanSUVgluc values) were independent predictors
f plaque inflammation as measured by FDG-PET imaging
Figs. 1 to 3). The ENTER regression also showed that
meanTBRgluc and SHSgluc were inversely associated with a
family history of CVD (Figs. 2 and 3).
The multiple regression analysis for non–glucose-corrected
FDG-PET data is presented in Online Table 1.
Multiple regressions in subgroups. Multiple linear re-
gression analyses in the subgroup of patients with and
patients without diabetic disease is presented in Table 4
after a similar procedure as described previously. In diabetic
subjects, BMI 30 kg/m2 continued to be significantly
associated with all of the 3 glucose-corrected FDG-PET
uptake parameters. In nondiabetic subjects, hypertension
showed the strongest association with the FDG-PET up-
take parameters. These and other associations are shown in
Table 4.
Again, results for the regression analysis for non–glucose-
tic Subjects
42 (32%)
Nondiabetic Subjects
n  89 (68%) p Value
.2 21.6 137.5 20.5 0.71
12 0.29 2.20 0.37 0.21
84 0.71 2.39 0.55 0.0001
95 0.30 2.01 0.33 0.34
.6 0.62 2.17 0.48 0.0001
29 0.48 2.31 0.43 0.42
06 0.90 2.50 0.61 0.0001
09 0.11 1.11 0 0.59
2 (18.5) 53 (81.5)
21 0.38 2.16 0.48 0.77
13 0.45 1.98 0.4 0.26
55 0.71 2.27 0.44 0.09
0 (45.5) 36 (54.5)
09 0.65 2.72 0.48 0.011
78 0.58 2.46 0.46 0.013
26 0.90 2.84 0.66 0.032
erial slices of the left and right carotid artery, a meanSUV value was derived for the carotid arteries.
r the 18F-fluorodeoxyglucose (FDG) blood pool activity was calculated. No statistically significant
e time. Whereas all of the glucose-corrected FDG uptake parameters were significantly higher in
rs. Dividing the patients into 2 groups of different pre-scan glucose levels by using the median of
atients without diabetes for all glucose-corrected FDG uptake values in the group of patients with
on. †Left and right jugular vein; meanSUV of the mean. ‡Glucose-corrected FDG uptake parameters
target-to-background ratio.Diabe
n 
136
2.
2.
1.
2
2.
3.
1.
1
2.
2.
2.
3
3.
2.
3.
f all art
nSUV fo
G uptak
ramete
s and p
cquisiticorrected FDG-PET data are presented in Online Table 2.
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June 5, 2012:2080–8 Type 2 Diabetes and Carotid Wall FDG UptakeTertile analysis. Online Table 3 shows clinical character-
istics stratified by tertiles of meanSUVgluc, meanTBRgluc, and
SHSgluc. The prevalence of type 2 diabetes and BMI 30
g/m2 were both significantly higher at higher tertiles of the
glucose-corrected FDG-PET uptake parameters.
orrelation between continuous BMI values and FDG
ptake parameters in the entire study population and the
ubgroups. Positive significant correlations were found be-
ween the continuous BMI values and all of the uncorrected
nd glucose-corrected FDG uptake parameters in the entire
tudy population and the 2 subgroups (r  0.25, p  0.02
or all), except TBRmax values in the total study population
and in nondiabetic patients, SUVmax values in diabetic
patients, as well as TBRmaxgluc and SHSgluc values in
ondiabetic patients.
istribution of FDG-PET uptake parameters according
o pre-scan glucose levels. Online Figure 1 depicts signif-
cantly increasing FDG uptake parameters (meanSUVgluc,
meanTBRgluc, and SHSgluc) by increments of fasting glucose
levels in patients with type 2 diabetes. Remarkably, FDG
uptake values in nondiabetic subjects were similar (SHSgluc)
r even slightly, but not significantly, higher (meanSUVgluc,
meanTBRgluc) compared with those of diabetic patients with
asting glucose levels within the normal range (6.1
mol/l) (Online Fig. 1).
iscussion
he aim of our study was to determine if the presence of
ype 2 diabetes was related to carotid wall FDG uptake.
his relation might therefore represent a link between
iabetic disease and carotid wall inflammation in a popula-
ion of patients with known CVD or multiple risk factors
Multiple Linear Regression Analyses in the Whole Study PopulationTable 3 Multiple Linear Regression Analyses in the Whole Stud
Glucose-Corrected FDG
Uptake Parameters Standardized Coefficient 
meanSUVgluc
Diabetes 0.324 0.
BMI 30 kg/m2 0.282 0.
Alcohol 0.157 0.
meanTBRgluc
Diabetes 0.317 0.
BMI 30 kg/m2 0.219 0.
Family history CVD 0.20 0.
Alcohol 0.197 0.
SHSgluc
Diabetes 0.298 0.
BMI 30 kg/m2 0.259 0.
Family history CVD 0.21 0.
Alcohol 0.163 0.
Multiple linear regression analyses with backward elimination to identify clinical risk factors of c
parameters in the whole study population. The mean standardized uptake value glucose leve
espectively, were the response variables; and the cardiovascular risk factors age 65 years, ma
moking, alcohol use, exercise, hypertension, diabetes, and family history of CVD were the expla
oefficient. Diabetes was the most significant predictor for carotid wall inflammation as depicted b
he results were highly consistent among the different FDG uptake values.
CI  confidence interval.or it. We used a cross sectional study design in a largerample population than previous studies (7–10) and performed
DG-PET imaging with protocols optimized for vessel wall
DG uptake (9,14). Our results demonstrate that diabetes was
Figure 1 Clinical Risk Factors of
Carotid Vessel Wall Inflammation
Differences in mean glucose-corrected standardized uptake value (meanSUVgluc) in
patients with diabetes and patients without diabetes and with and without body
mass index (BMI) values 30 kg/m2 are shown. Both variables were identified as
significantly (p  0.05) independent predictors for carotid wall inflammation as
depicted by meanSUVgluc values. Data are presented as median (bold line), 25th to
75th percentile (box), and 5th to 95th percentile (whiskers). The circle repre-
sents outliers. The p value for each of the given independent predictors for carotid
wall inflammation as depicted by meanSUVgluc values is adjusted for the other sig-
nificant variable given in Table 3 (diabetes, body mass index 30 kg/m2, and
alcohol). Alcohol failed to show a statistically significant association (p  0.05)
with the meanSUVgluc values in the ENTER regression model and therefore is not
shown as an independent predictor in this figure.
g Glucose-Corrected FDG Uptake Parameterspulation Using Glucose-Corrected FDG Uptake Parameters
CI Adjusted R2 Significance p Value
0.201 0.0001
0.656 0.0001
0.587 0.001
0.411 0.051
0.229 0.0001
0.570 0.0001
0.440 0.006
0.051 0.012
0.406 0.013
0.234 0.0001
0.737 0.0001
0.656 0.001
0.084 0.009
0.494 0.038
essel wall inflammation are depicted by glucose-corrected 18F-fluorodeoxyglucose (FDG) uptake
UVgluc), mean target-to-background ratio (meanTBRgluc), and single hottest segment (SHSgluc),
body mass index (BMI) 30 kg/m2, statin medication, history of cardiovascular disease (CVD),
ariables. Variables were retained in the model when p  0.10.  is the standardized regression
the FDG uptake parameters, followed by obesity as depicted by BMI values 30 kg/m2. Notably,Usiny Po
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Type 2 Diabetes and Carotid Wall FDG Uptake June 5, 2012:2080–8significantly associated with the FDG uptake in the carotid
wall. Additionally, we showed that obesity was also related to
carotid wall inflammation as depicted by FDG-PET. In the
nondiabetic group, hypertension was the leading variable as-
sociated with inflammation measured by FDG-PET uptake.
We also identified increasing fasting glucose levels in diabetic
patients to be significantly associated with increments of the
FDG uptake, which might be indicative of a higher propensity
for carotid wall inflammation with increasing degrees of
hyperglycemia.
FDG-PET/CT methodology. The rationale for choosing
to perform glucose correction of the FDG uptake is based
on several oncology studies, which suggest that elevated
pre-scan glucose levels can influence significantly the tu-
mor’s uptake of FDG during PET imaging (12,20,21). One
potential pitfall to using a glucose correction, however, is a
resultant increase in the variability of the SUV measure-
ments (22). The role of glucose correction of FDG uptake
in noncancer lesions is not well understood. However, we
believe, because the mechanism of uptake of FDG into
inflammatory cells is the same as for tumor cells, that the
same correction should be applied. In accordance with the
European Association of Nuclear Medicine procedure guide-
lines for tumor PET imaging, we have also presented the
Figure 2 Clinical Risk Factors of
Carotid Vessel Wall Inflammation
Differences in the mean target-to-background ratio (meanTBRgluc) values in patients
with diabetes and patients without diabetes, body mass index (BMI) 30 kg/m2,
and alcohol are illustrated. All variables were identified as significantly (p  0.05)
independent predictors for carotid wall inflammation as depicted by the meanTBRgluc.
Family history is independently associated with a decreased risk of carotid wall
inflammation as revealed by significantly lower meanTBRgluc values in patients
with a family history of cardiovascular disease. Data are presented as median
(bold line), 25th to 75th percentile (box), and 5th to 95th percentile (whis-
kers). Circles represent outliers. The p value for each of the given independent
predictors for carotid wall inflammation as depicted by meanTBRgluc values is
adjusted for the other significant variables given in Table 3 (diabetes, BMI 30
kg/m2, alcohol, and family history of cardiovascular disease).results without glucose correction (Online Appendix) (16).Multivariate regression analyses revealed an unexpected
negative association between diabetes and the uncorrected
meanSUV values of the carotids in our study. This finding is in
contrast to the well-known clinical impact of diabetes on
CVD. However, future studies still need to be performed to
investigate whether the corrected or uncorrected FDG uptake
values are more sensitive surrogate markers for carotid wall
inflammation by correlating both FDG uptake parameters
with the histological assessment of vascular inflammation.
Impact of circulation time on FDG uptake. The optimal
circulation time before imaging plaque inflammation has
still not been definitively established. Typically, a circulation
time between 1 h and 3 h is used by most groups
(4,5,23,24). To exclude an impact of the FDG circulation
time on the FDG uptake in patients with and patients
without diabetes, we compared the FDG circulation time
between both groups of patients. As we did not find a
statistically significant difference, the differences of the
FDG uptake between diabetic patients and nondiabetic
patients cannot be explained by different FDG circulation
times in both groups.
Type 2 diabetes and carotid wall inflammation. We
observed that type 2 diabetes and obesity (BMI) were inde-
pendently associated with increased FDG-PET uptake values.
In patients with type 2 diabetes, obesity and smoking added
additional risk for increased FDG uptake in the carotid wall. In
Figure 3 Clinical Risk Factors of
Carotid Vessel Wall Inflammation
Differences in single hottest segment (SHSgluc) values in patients with diabe-
tes and patients without diabetes, body mass index (BMI) 30 kg/m2, and
alcohol are shown. All variables were identified as significantly (p  0.05) inde-
pendent predictors for carotid wall inflammation as depicted by the SHSgluc
value. Family history is independently associated with a decreased risk of
carotid wall inflammation as revealed by significantly lower SHSgluc values in
patients with a family history of cardiovascular disease. Data are presented as
median (bold line), 25th to 75th percentile (box), and 5th to 95th percentile
(whiskers). The circle represents outliers. The p value for each of the given
independent predictors for carotid wall inflammation as depicted by SHSgluc
values is adjusted for the other significant variables given in Table 3 (diabetes,
BMI 30 kg/m2, alcohol, and family history of cardiovascular disease).
2087JACC Vol. 59, No. 23, 2012 Bucerius et al.
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be significantly associated with carotid wall inflammation as
depicted by all FDG uptake parameters.
Our results are in agreement with some of the previously
published studies evaluating the association between cardio-
vascular risk factors and vessel wall inflammation. In a
case-control study of patients with type 2 diabetes, impaired
glucose tolerance, and controls, Kim et al. (10) reported
higher TBRmax values in both study groups compared with
the control group. As in the present study, they also
observed increasing prevalence of diabetes with increments
of maximum TBR values as depicted by tertiles. However,
glucose correction was not used in their study, and that may
have resulted in an underestimation of FDG-PET uptake
values.
Previous studies have demonstrated the link between
circulating insulin levels and its effect on the over-expression
of glucose transporter protein types (10,11). Tahara et al. (7)
have also shown that carotid inflammation was associated
with several cardiovascular risk factors, including a homeo-
stasis model assessment of insulin resistance. They found
obesity, as assessed by waist circumference and use of
hypertensive medication, to be significantly associated with
carotid wall inflammation. However, fewer subjects in their
population had CVD, and the cardiovascular risk profile for
their population was much lower primarily because their
retrospective analysis was done among cancer patients. In
our study, we found a relationship between hypertension
Multiple Linear Regression Analyses in Subjects With and WithoutTable 4 Multiple Linear Regression Analyses in Subjects With
Glucose-Corrected FDG
Uptake Parameters Standardized Coefficient 
meanSUVgluc
Diabetic subjects
BMI 30 kg/m2 0.400 0.
Nondiabetic subjects
Hypertension 0.325 0.
BMI 30 kg/m2 0.212 0.
meanTBRgluc
Diabetic subjects
BMI 30 kg/m2 0.357 0.
Smoking 0.312 0.
Nondiabetic subjects
Hypertension 0.361 0.
SHSgluc
Diabetic subjects
BMI 30 kg/m2 0.388 0.
Smoking 0.324 0.
Nondiabetic subjects
Hypertension 0.345 0.
Multiple linear regression analyses with backward elimination to identify clinical risk factors of
parameters in diabetic subjects and nondiabetic subjects. The meanSUVgluc, mean target-to-back
cardiovascular risk factors age65 years, male sex, body mass index (BMI)30 kg/m2, statin me
history of CVD were the explanatory variables. Variables were retained in the model when p 0.05
for diabetic and nondiabetic patients. BMI 30 kg/m2 and smoking were significantly associate
nondiabetic subjects, hypertension was consistently associated with all FDG uptake parameters.
CI  confidence interval.and carotid wall inflammation measured by FDG-PET inthe nondiabetic group and a relationship between BMI and
carotid wall FDG uptake for both diabetics and nondiabetic
patients.
Relationship between fasting glucose levels and carotid
wall FDG uptake. Studies have shown that hyperglycemia
leads to increased oxidative stress producing endothelial dys-
function (25). Several observational studies have shown an
association between levels of glycemia and macrovascular
events in patients with diabetes (26,27). Early data from the
UK Prospective Diabetes Study suggested a protective effect of
improved glucose control on CVD incidence and mortality
(26,29). Results from our study seem to support these findings,
as we found similar meanTBRgluc values in patients with
diabetes and fasting glucose levels6.1 mmol/l compared with
nondiabetic patients (p  0.985). We also observed higher
FDG uptake parameters with increasingly poorer glycemic
control.
Relationship between hypertension and carotid wall
FDG uptake. Two recently published trials prospectively
investigated the impact of hypertension on cardiovascular
risk in patients with and patients without diabetic disease
(28,29). Both trials found hypertension to be associated
with a higher risk of CVD among diabetic patients but
failed to show a significant interaction between diabetes and
increased blood pressure. We found that hypertension
showed a significant association with carotid wall FDG
uptake only in the nondiabetic subgroup.
Study limitations. Firstly, we did not obtain serum lipid
etic Diseaseithout Diabetic Disease
CI Adjusted R2 Significance p Value
0.139 0.009
.989 0.009
0.153 0.0001
.597 0.002
.483 0.036
0.220 0.003
.793 0.014
.405 0.031
0.185 0.0001
.555 0.0001
0.256 0.001
.208 0.007
.081 0.022
0.109 0.001
.685 0.001
vessel wall inflammation is depicted by glucose-corrected 18F-fluorodeoxyglucose (FDG) uptake
ratio (meanTBRgluc), and single hottest segment (SHSgluc) were the response variables; and the
, history of cardiovascular disease (CVD), smoking, alcohol use, exercise, hypertension, and family
st model is shown.  is the standardized regression coefficient. The same models were calculated
all FDG uptake parameters (except smoking with regard to meanSUVgluc) in diabetic subjects. InDiaband W
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Therefore, we could not address whether there was a causal
relationship between the presence of diabetic disease and
vessel wall inflammation. Thirdly, it is unknown whether
vessel wall FDG uptake is predictive of progression of
disease or future cardiovascular events in diabetic patients.
Longitudinal studies are currently under way to establish
such a relation. Finally, in the present study, image analyses
were performed by only 1 reader, which might reduce
statistical noise related to interobserver variation but might
raise concerns regarding intraobserver bias; however, previ-
ous reports demonstrated that this method has good inter-
observer and intraobserver reproducibility (15).
Conclusions
In the present study, we show that type 2 diabetes has a
significant impact on the FDG uptake in the wall of the
carotid arteries. Obesity (BMI30 kg/m2) and smoking are
lso significantly associated with FDG-PET uptake param-
ters in diabetic patients. For nondiabetic patients, hyper-
ension was significantly associated with carotid wall inflam-
ation. Furthermore, the degree of the carotid wall FDG
ptake increases with increments of fasting glucose levels in
iabetic patients. Whether the glucose-corrected FDG
ptake parameters are indicative of vessel wall inflammation
as to be determined by future studies.
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